AMAnna Morra

Anna Morra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna Morra has a total of 174 co-authors. Here are the top co-authors by number of shared publications:

  • Anna Jakubowska

    Department of Genetics and Pathology, International Hereditary Cancer Center Pomeranian Medical University Szczecin Poland

    2 shared publications
  • Anna Marie Mulligan

    Department of Laboratory Medicine and Pathobiology University of Toronto Toronto Ontario Canada

    2 shared publications
  • Anthony Howell

    Division of Cancer Sciences University of Manchester Manchester UK

    2 shared publications
  • Arto Mannermaa

    Translational Cancer Research Area University of Eastern Finland Kuopio Finland

    2 shared publications
  • Camilla Wendt

    Department of Clinical Science and Education, Södersjukhuset Karolinska Institutet Stockholm Sweden

    2 shared publications
  • Dimitrios Mavroudis

    Department of Medical Oncology University Hospital of Heraklion Heraklion Greece

    2 shared publications

Latest Publications

  • Open Access

    Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer‐specific survival

    by Anna Morra, Maartje A. C. Schreurs, Irene L. Andrulis, Hoda Anton‐Culver, Annelie Augustinsson, Matthias W. Beckmann, Sabine Behrens, Stig E. Bojesen, Manjeet K. Bolla, Hiltrud Brauch, et al.

    Background: Breast cancer (BC) patients with a germline CHEK2 c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC‐specific survival (BCSS) compared to non‐carriers.Aim: To assessed the associations of CHEK2 c.1100delC, radiotherapy, and systemic treatment with CBC risk and BCSS.Methods: Analyses were based on 82,701 women diagnosed with a first primary invasive BC including 963 CHEK2 c.1100delC carriers; median follow‐up was 9.1 years. Differential associations with treatment by CHEK2 c.1100delC status were tested by including interaction terms in a multivariable Cox regression model. A multi‐state model was used for further insight into the relation between CHEK2 c.1100delC status, treatment, CBC risk and death.Results: There was no evidence for differential associations of therapy with CBC risk by CHEK2 c.1100delC status. The strongest association with reduced CBC risk was observed for the combination of chemotherapy and endocrine therapy [HR (95% CI): 0.66 (0.55–0.78)]. No association was observed with radiotherapy. Results from the multi‐state model showed shorter BCSS for CHEK2 c.1100delC carriers versus non‐carriers also after accounting for CBC occurrence [HR (95% CI): 1.30 (1.09–1.56)].Conclusion: Systemic therapy was associated with reduced CBC risk irrespective of CHEK2 c.1100delC status. Moreover, CHEK2 c.1100delC carriers had shorter BCSS, which appears not to be fully explained by their CBC risk.


  • Open Access

    The impact of coding germline variants on contralateral breast cancer risk and survival

    by Anna Morra, Nasim Mavaddat, Taru A Muranen, Thomas U Ahearn, Jamie Allen, Irene L Andrulis, Päivi Auvinen, Heiko Becher, Sabine Behrens, Carl Blomqvist, et al.